Top of this page
Skip navigation, go straight to the content

Investors UCB Governance

UCB Governance

 The Company is administered by a Board of Directors and run by an Executive Committee, whose respective functions and responsibilities are clearly defined in the Corporate Governance Charter.

The General Meeting of Shareholders is convened once a year, on the last Thursday of April, for its Ordinary meeting. A General Meeting of Shareholders may also be called in Special or Extraordinary circumstances whenever the Company interests dictate. Rules relating to General Meetings and main rights and obligations of Shareholders are further detailed in the Corporate Governance Charter.

 

Board of Directors

 

UCB Board and Committees

To enhance the overall effectiveness of the Board by ensuring focus, oversight and monitoring of sensitive areas, the Board has created three specialist committees:

Board of Directors

  • 13 members
  • 7 independent directors (54%)
  • 5 nationalities
  • 5 women (38%)
  • 4-year mandate
  • age limit: 70

 

Executive Committee

  • 8 members
  • 5 nationalities
  • 2 women (25%)

 

Composition of the Board of Directors

Update: April 2020 (post AGM)

Evelyn du Monceau

Chair of the Board

Gerhard Mayr

First appointed in 1984

End of term in 2023

Chair of the GNCC

Pierre Gurdjian

Vice Chairman & Independent Director

image description

First appointed in 2016

End of term in 2024

Member of the GNCC

Jean-Christophe Tellier

Executive Director

image description

First appointed in 2014

End of term in 2022

 

Jan Berger

Independent Director

image description

First appointed in 2019

End of term in 2023

 

Alice Dautry

Independent Director

image description

First appointed in 2015

End of term in 2023

Member of the Scientific Committee

Kay Davies

Independent Director

image description

First appointed in 2014

End of term in 2022

Chair of the Scientific Committee

Member of the GNCC

Albrecht De Graeve

Independent Director

image description

First appointed in 2010

End of term in 2021

Chairman of the Audit Committee

Roch Doliveux

Director

image description

Appointed in 2017

End of term in 2021

 

Charles-Antoine Janssen

Director

image description

First appointed in 2012

End of term in 2024

Member of the Audit Committee

Cyril Janssen

Director

image description

First appointed in 2015

End of term in 2023

 

Viviane Monges

Independent Director

image description

First appointed in 2017

End of term in 2021

Member of the Audit Committee

Cédric van Rijckevorsel

Director

image description

First appointed in 2014

End of term in 2022

 

Ulf Wiinberg

Independent Director

image description

First appointed in 2016

End of term in 2024

Member of the Audit Committee

 

Composition of the Executive Committee

Update: April 2020

 

We have adapted the organization structure on four pillars around which we are creating value for each patient, centered by our focus and integrated across functional teams around different patient populations.

Jean-Christophe Tellier

Jean-Christophe Tellier

Chief Executive Officer &
Chairman of the Executive Committee

Joined UCB in 2011
Appointed as CEO in 2015

 

Iris Löw-Friedrich

Pascale Richetta

Executive Vice President &
Chief Medical Officer

Joined UCB in 2006
Appointed in 2008

Emmanuel Caeymaex

Emmanuel Cayemaex

Executive Vice President
Immunology Solutions & Head of U.S.

Joined UCB in 1994
Appointed in 2015

 

Kirsten Lund-Jurgensen

image description

Executive Vice President
Supply & Technology Solutions

Joined UCB in 2019
Appointed in 2019

Jean Luc Fleurial

Iris Loew-Friedrich

Executive Vice President &
Chief Human Resources Officer

Joined UCB in 2017
Appointed in 2017

 

Dhaval Patel 

image description

Executive Vice President &
Chief Scientific Officer

Joined UCB in 2017
Appointed in 2017

Bill Silbey

image description

Executive Vice President &
General Counsel

Joined UCB in 2011
Appointed in March 2019

Charl van Zyl

image description

Executive Vice President
Neurology Solutions & Head of EU / International

Joined UCB in 2017
Appointed in 2017

CFO transition

Detlef Thielgen stepped down from the Executive Committee as of 10 April 2020.

Sandrine Dufour will join UCB and take over the CFO position as of 1 July 2020.

Jean-Christophe Tellier will ensure the interim role of CFO in the meantime.

Shareholders and shareholders meetings

Find out about UCB shareholders, their transparency notifications and our shareholders meetings on the dedicated webpage.

Main corporate governance documents

UCB SA/NV has adopted the 2020 edition of the Belgian Code of Corporate Governance as its reference Code taking into account the specific international aspects of the Company. As part of these rules, UCB SA/NV, as a listed company, has adopted a Corporate Governance Charter and a Code of Conduct, including a Dealing Code.

The Corporate Governance Charter established by the Board of Directors aims at providing a comprehensive and transparent disclosure of the Company’s governance. It defines the system of checks and balances between the shareholders/investors, the Board and the management to shape an efficiently functioning company, ideally geared to produce long-term sustainable value for all the Company’s stakeholders. It will be continuously updated as required.

Articles of Association

Special reports of the Board

Remuneration policy

Corporate governance charter

 
 

Dealing code

 
 

Code of conduct